tirzepatide day 3 3: Mounjaro (Tirzepatide – weekly injection) Class: Dual GLP-1 and GIP receptor agonist Avg Weight Loss: ~20% of baseline weight (SURMOUNT-1 trial) FDA Status: Approved for type 2 diabetes; Fast-tracked for Tirzepatide Dosage Guide and Chart

Mr Monu received fellowship support from CSIR, New Delhi

doi: 10.1055/s-0042-101794 [DOI] [PubMed] [Google Scholar] 82

Always list all vitamins, minerals, herbal products, and over-the-counter supplements you takePlexusDx clinicians screen these during your medication review to prevent unintended blood sugar crashes or reduced medication effectiveness

DPP-4 inhibitors: Linagliptin: hepatobiliary excretion (no dose adjustment required in patients with renal impairment, making it preferred) Other DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, and alogliptin) are predominantly eliminated by the kidneys, so dosage must be adjusted in cases of severe renal dysfunction

Targeting GLP-1 receptors to reduce nicotine use disorder: preclinical and clinical evidence